3- (2- ((phenylamino)carbonyl)ethenyl)- 4,6- dichloroindole- 2- carboxylic acid

structure in first source

Also Known As:

1H-indole-2-carboxylic acid, 4,6-dichloro-3-((1E)-3-oxo-3-(phenylamino)-1-propenyl)-, monosodium salt; 4,6-dichloro-3-((E)-2-(phenylcarbamoyl)vinyl)indole-2-carboxylic acid; GV 150526A; GV-150526A; GV-150526X; GV150526; GV150526A; Gavestinel; gavestinel sodium

Networked: 29 relevant articles (5 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - 3-(2-((phenylamino)carbonyl)ethenyl)-4,6-dichloroindole-2-carboxylic acid: 29

Experts

1.	Lees, Kennedy R: 6 articles (01/2006 - 10/2003)
2.	GAIN International Steering Committee and Investigators: 4 articles (09/2004 - 10/2003)
3.	Lees, K R: 4 articles (01/2004 - 02/2000)
4.	Aslanyan, Stella: 3 articles (09/2004 - 10/2003)
5.	Weir, Christopher J: 3 articles (09/2004 - 10/2003)
6.	Barnaby, R J: 3 articles (04/2003 - 02/2000)
7.	Chiu, David: 2 articles (05/2010 - 01/2006)
8.	Kaste, M: 2 articles (01/2004 - 06/2000)
9.	Kajbaf, M: 2 articles (04/2003 - 09/2000)
10.	Diener, H C: 2 articles (01/2001 - 06/2000)

Related Diseases

1.	Ischemic Stroke 05/01/2005 - "Both trials reported that gavestinel was ineffective in ischemic stroke. " 04/04/2001 - "In this study, gavestinel administered up to 6 hours after an acute ischemic stroke did not improve functional outcome at 3 months." 06/03/2000 - "Treatment with gavestinel within 6 h of acute ischaemic stroke did not improve outcome." 01/01/2006 - "The safety and efficacy of GV150526 were studied in two phase III randomized placebo-controlled clinical trials of acute ischemic stroke patients within 6 h from onset [The Glycine Antagonist in Neuroprotection (GAIN) International and GAIN Americas Trials]. " 09/01/2004 - "We studied all patients of the Glycine Antagonist (gavestinel) In Neuroprotection (GAIN) International Trial with ischemic stroke alive at day 7, excluding patients with hemorrhagic events and deaths from nonstroke-related causes. "
2.	Stroke (Strokes) 01/01/2004 - "While planning the GAIN International Study of gavestinel in acute stroke, a sequential triangular test was proposed but not implemented. " 01/01/2004 - "How a sequential design would have affected the GAIN International Study of gavestinel in stroke." 11/01/2001 - "Gavestinel produces no benefit for stroke patients, study finds." 01/01/2001 - "GV150526 was generally well tolerated in patients with a clinical diagnosis of acute stroke and formal efficacy studies were considered justified." 01/01/2001 - "The purpose of this randomised, double-blind, multicentre, placebo-controlled trial was to assess the safety and population pharmacokinetics of GV150526 in patients with a clinical diagnosis of acute stroke. "
3.	Infarction (Infarctions) 06/01/1997 - "Postischemia administration of GV150526 (3 mg/kg i.v.) up to 6 h post-MCAo resulted in a significant reduction of the infarct volume measured histologically 24 h later. " 01/01/2006 - "Consistent with the clinical outcomes in the GAIN trials, no effects of gavestinel on ischemic infarction was observed. " 01/01/2006 - "A planned MRI substudy within these trials investigated the effect of gavestinel on infarct volume. " 01/01/2006 - "No effects of gavestinel on infarct volume were observed in the primary or other analyses. " 02/01/2000 - "GV150526, a selective glycine site antagonist, reduces infarct volume in rats with focal cerebral ischemia. "
4.	Brain Ischemia (Cerebral Ischemia) 05/11/2001 - "GV150526 was administered at a dose of 3 mg/kg i.v. T2-weighted (T2W) and diffusion weighted (DW) images were acquired at 6, 24 and 144 h after the establishment of the cerebral ischemia. " 09/09/1999 - "Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia." 02/01/2000 - "GV150526, a selective glycine site antagonist, reduces infarct volume in rats with focal cerebral ischemia. " 10/08/1997 - "The nanomolar potency of GV 150526A in reducing NMDA receptor function by competitively acting at the strychnine-insensitive glycine sites suggests that GV 150526A could be effective in vivo to reduce NMDA receptor over-stimulation, like in brain ischemia."
5.	Cerebral Infarction 01/01/2006 - "Effect of the Glycine Antagonist Gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI Substudy."

Related Drugs and Biologics

1.	Glycine (Aminoacetic Acid)
2.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
3.	3- (2- ((phenylamino)carbonyl)ethenyl)- 4,6- dichloroindole- 2- carboxylic acid
4.	eliprodil
5.	N-Methylaspartate (NMDA)
6.	selfotel
7.	aptiganel
8.	Strychnine
9.	Dextrorphan
10.	Neuroprotective Agents

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Administration